MedTrace Logo

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

NCT04890795 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2021-05-18

No results posted yet for this study

Summary

Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence or progression after second-line and above treatment,Evaluation of the effectiveness of al8326 monotherapy in small cell lung cancer.

Conditions

Interventions

DRUG

AL8326 tablets

10mg/tablet;Oral administration, once daily.

Sponsors & Collaborators

  • Advenchen Laboratories Nanjing Ltd.

    lead INDUSTRY

Principal Investigators

  • xiaochun Zhang · The Affiliated Hospital of Qingdao University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-19
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04890795 on ClinicalTrials.gov